TNF-α blockers, such as infliximab, adalimumab and etanercept, are currently approved by the FDA for the treatment of chronic inflammatory diseases such as RA, Crohn’s disease and ankylosing spondylitis. Here, TNF is linked to rheumatoid arthritis.